---
title: "康哲藥業單抗注射液「MG-K10」上市申請獲受理"
description: "康哲藥業公佈，旗下德鎂醫藥連同其附屬擁有共同開發權和獨家商業化權利的 1 類新藥抗 IL-4Rα MG-K10 人源化單抗注射液 (通用名︰柯美奇拜單抗注射液，「MG-K10」) 中國上市許可申請獲中國國家藥品監督管理局受理。「MG-K10」擬用於治療外用藥控制不佳或不適用外用藥治療的成人中重度特應性皮炎。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/263529522.md"
published_at: "2025-10-30T13:12:19.000Z"
---

# 康哲藥業單抗注射液「MG-K10」上市申請獲受理

> 康哲藥業公佈，旗下德鎂醫藥連同其附屬擁有共同開發權和獨家商業化權利的 1 類新藥抗 IL-4Rα MG-K10 人源化單抗注射液 (通用名︰柯美奇拜單抗注射液，「MG-K10」) 中國上市許可申請獲中國國家藥品監督管理局受理。「MG-K10」擬用於治療外用藥控制不佳或不適用外用藥治療的成人中重度特應性皮炎。

康哲藥業 (00867.HK) 公佈，旗下德鎂醫藥連同其附屬擁有共同開發權和獨家商業化權利的 1 類新藥抗 IL-4Rα MG-K10 人源化單抗注射液 (通用名︰柯美奇拜單抗注射液，「MG-K10」) 中國上市許可申請獲中國國家藥品監督管理局受理。

「MG-K10」擬用於治療外用藥控制不佳或不適用外用藥治療的成人中重度特應性皮炎。

### Related Stocks

- [00867.HK - 康哲藥業](https://longbridge.com/zh-HK/quote/00867.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Insilico and CMS launch drug discovery collaborations for CNS diseases | Insilico Medicine has partnered with China Medical System (CMS) to launch AI drug discovery collaborations targeting cen | [Link](https://longbridge.com/zh-HK/news/275583451.md) |
| JSW MG Motor India Unveils MG MAJESTOR, D+ Segment SUV | JSW MG MOTOR INDIA UNVEILS MG MAJESTOR, D+ SEGMENT SUV | [Link](https://longbridge.com/zh-HK/news/275738598.md) |
| 11:30 ETInventHelp Inventors Develop New Vaporizer and Attachment (PTA-448) | InventHelp has announced the development of a new vaporizer and attachment called the SPLIF T, designed to allow users t | [Link](https://longbridge.com/zh-HK/news/276357553.md) |
| Sk Innovation Selected As Developer Of $2.3 Billion LNG Power Project In Vietnam | SK Innovation Co Ltd :SK INNOVATION: SELECTED AS DEVELOPER OF $2.3 BILLION LNG POWER PROJECT IN VIETNAM | [Link](https://longbridge.com/zh-HK/news/276292221.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/zh-HK/news/276051793.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。